BioSpace News Archive

The U.S. Food and Drug Administration approved Eli Lilly’s Reyvow (lasmiditan) for the acute treatment of migraines.

Researchers found that an injectable hormone called tesamorelin decreases liver fat and prevented liver fibrosis in this patient population.

The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo.

A new study shows that a PARP inhibitor combined with a DNA methyltransferase inhibitor may be a new way of treating some lung cancers.

Roche announced results from its Phase III PEMPHIX trial evaluated MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris.

The U.S. Food and Drug Administration approved Janssen Pharmaceutical’s Xarelto for the prevention of venous thromboembolism, or blood clots, in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.

First and only Adenosine A2A receptor antagonist for use in Parkinson’s disease in the U.S.

Minimally invasive carotid artery disease treatment reduces stroke risk

Zymergen Signing Reinforces BioMed Realty’s Growth in the San Francisco Bay Area

Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the 2019 BIO Investor Forum on Tuesday, October 22 at 4:00 pm PT